420 related articles for article (PubMed ID: 25225419)
1. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis.
Wang HT; Yao YH; Li BG; Tang Y; Chang JW; Zhang J
J Clin Oncol; 2014 Oct; 32(30):3383-90. PubMed ID: 25225419
[TBL] [Abstract][Full Text] [Related]
2. Platinum sensitivity in metastatic prostate cancer: does histology matter?
Humeniuk MS; Gupta RT; Healy P; McNamara M; Ramalingam S; Harrison M; George D; Zhang T; Wu Y; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):92-99. PubMed ID: 29230006
[TBL] [Abstract][Full Text] [Related]
3. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
[No Abstract] [Full Text] [Related]
4. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.
Mosquera JM; Beltran H; Park K; MacDonald TY; Robinson BD; Tagawa ST; Perner S; Bismar TA; Erbersdobler A; Dhir R; Nelson JB; Nanus DM; Rubin MA
Neoplasia; 2013 Jan; 15(1):1-10. PubMed ID: 23358695
[TBL] [Abstract][Full Text] [Related]
5. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract][Full Text] [Related]
7. Clinical features of neuroendocrine prostate cancer.
Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
[TBL] [Abstract][Full Text] [Related]
8. Molecular events in neuroendocrine prostate cancer development.
Wang Y; Wang Y; Ci X; Choi SYC; Crea F; Lin D; Wang Y
Nat Rev Urol; 2021 Oct; 18(10):581-596. PubMed ID: 34290447
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
[TBL] [Abstract][Full Text] [Related]
10. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.
Lin D; Dong X; Wang K; Wyatt AW; Crea F; Xue H; Wang Y; Wu R; Bell RH; Haegert A; Brahmbhatt S; Hurtado-Coll A; Gout PW; Fazli L; Gleave ME; Collins CC; Wang Y
Oncotarget; 2015 Jan; 6(3):1806-20. PubMed ID: 25544761
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.
Huang G; Zhang H; Shi H; Zhang W; Wang T; Wang Z; Chen Q; Lian B; Li J; Yang G
World J Surg Oncol; 2022 Dec; 20(1):407. PubMed ID: 36572885
[TBL] [Abstract][Full Text] [Related]
12. SRRM4 gene expression correlates with neuroendocrine prostate cancer.
Li Y; Zhang Q; Lovnicki J; Chen R; Fazli L; Wang Y; Gleave M; Huang J; Dong X
Prostate; 2019 Jan; 79(1):96-104. PubMed ID: 30155992
[TBL] [Abstract][Full Text] [Related]
13. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis.
Zaffuto E; Pompe R; Zanaty M; Bondarenko HD; Leyh-Bannurah SR; Moschini M; Dell'Oglio P; Gandaglia G; Fossati N; Stabile A; Zorn KC; Montorsi F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2017 Oct; 15(5):e793-e800. PubMed ID: 28506524
[TBL] [Abstract][Full Text] [Related]
14. Utility of FDG-PET in clinical neuroendocrine prostate cancer.
Spratt DE; Gavane S; Tarlinton L; Fareedy SB; Doran MG; Zelefsky MJ; Osborne JR
Prostate; 2014 Aug; 74(11):1153-9. PubMed ID: 24913988
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of neuroendocrine prostate cancer.
de Kouchkovsky I; Chan E; Schloss C; Poehlein C; Aggarwal R
Prostate; 2024 Apr; 84(5):426-440. PubMed ID: 38173302
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
Beltran H; Rickman DS; Park K; Chae SS; Sboner A; MacDonald TY; Wang Y; Sheikh KL; Terry S; Tagawa ST; Dhir R; Nelson JB; de la Taille A; Allory Y; Gerstein MB; Perner S; Pienta KJ; Chinnaiyan AM; Wang Y; Collins CC; Gleave ME; Demichelis F; Nanus DM; Rubin MA
Cancer Discov; 2011 Nov; 1(6):487-95. PubMed ID: 22389870
[TBL] [Abstract][Full Text] [Related]
17. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study.
Zhu J; Liang X; Wu D; Chen S; Yang B; Mao W; Shen D
Medicine (Baltimore); 2021 Apr; 100(15):e25237. PubMed ID: 33847621
[TBL] [Abstract][Full Text] [Related]
19. Imaging Somatostatin Receptor Activity in Neuroendocrine-differentiated Prostate Cancer.
Mori H; Nakajima K; Kadomoto S; Mizokami A; Ikeda H; Wakabayashi H; Kinuya S
Intern Med; 2018 Nov; 57(21):3123-3128. PubMed ID: 29877274
[TBL] [Abstract][Full Text] [Related]
20. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
Li Y; Donmez N; Sahinalp C; Xie N; Wang Y; Xue H; Mo F; Beltran H; Gleave M; Wang Y; Collins C; Dong X
Eur Urol; 2017 Jan; 71(1):68-78. PubMed ID: 27180064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]